Navigation Links
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses.The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better(P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients will respond to adjuvant treatments. The researchers suggest that the technique of DNA microarray analysis could be developed to help breast cancer patients who do not benefit from adjuvant therapy, and avoid painful unnecessary treatments and wastage of healthcare resources.


'"/>

Source:Karolinska Institutet


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
3. Breakthrough Microarray-based Technology for the Study of Cancer
4. Nanogen Issued Patent for Electronic Microarray With Memory
5. Characterizing Skin Cancer by Microarrays
6. Microarrays as phenotype
7. $6.5 Million Grant for Microarray Center at Yale School of Medicine
8. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Novel technology detects human DNA mutations
11. Novel antiviral technology inhibits RSV infection in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
Breaking Biology Technology: